This bills requires that no manufacturer or wholesale distributor may sell or offer to sell an essential off-patent or generic drug at a price that results in price gouging. Under the bill, price gouging means increasing the price of an essential off-patent or generic drug if both of these conditions apply: 1) the price increase is excessive and not justified by the cost of producing the drug or the cost of appropriately expanding access to the drug; and 2) the price increase results in a consumer who is prescribed the drug having no meaningful choice about whether to purchase the drug because the drug is important to the consumer’s health or because insufficient competition exists in the market for the drug.